Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Salivary Gland Neoplasms × apalutamide × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 85 Neoplasm Metastasis 4 Prostatic Neoplasms, Castration-Resistant 3 Prostatic Diseases 2 Non-metastatic Castration-resistant Prostate Cancer 2 Genital Diseases, Male 2 Urogenital Neoplasms 1 Stage II Prostate Adenocarcinoma 1 Small Cell Lung Carcinoma 1 Sleep Initiation and Maintenance Disorders 1 Salivary Gland Neoplasms 1 Prostate Cancer With ≤10 Bone Metastases 1 Prostate Cancer Metastatic Disease 1 Prostate Cancer Metastatic 1 Prostate Adenocarcinoma 1 Patient Preference 1 Non-Muscle Invasive Bladder Urothelial Carcinoma 1 Newly Diagnosed Oligometastatic Prostate Cancer 1 Neoplasms by Site 1 Neoplasms 1 Metastatic Hormone-sensitive Prostate Cancer 1 Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1 Metastatic Castration-sensitive Prostate Cancer 1 Metastatic Castration-resistant Prostate Neoplasms 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castration-Resistant Prostate Cancer 1 Metastatic Castrate-sensitive Prostate Cancer 1 Low Risk Prostate Cancer 1 High-Risk and Oligometastatic Prostate Cancer 1 High Risk Prostate Cancer 1

Interventions

Docetaxel 16 Cisplatin 15 Carboplatin 12 Radiotherapy 9 Magnetic Resonance Spectroscopy 9 Cetuximab 9 Biopsy 9 pembrolizumab 8 Paclitaxel 8 Immunohistochemistry 8 Erlotinib Hydrochloride 8 Trastuzumab 7 Radiotherapy, Intensity-Modulated 7 Chemotherapy, Adjuvant 7 Specimen Handling 6 Gemcitabine 6 Radiotherapy, Conformal 5 Vorinostat 4 Taxes 4 Radiosurgery 4 Gene Expression Profiling 4 Fluorodeoxyglucose F18 4 Capecitabine 4 Bevacizumab 4 trastuzumab deruxtecan 3 darolutamide 3 Surgical Procedures, Operative 3 Sorafenib 3 Radiation 3 Polymerase Chain Reaction 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04325828 2026-02-13

YATAGARASU

Janssen Pharmaceutical K.K.

Phase 2 Active not recruiting

31 enrolled 15 charts

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡